FDG-PET / PET-CT for hematologic oncology
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and investigational uses of 18F-FDG PET or PET/CT for diagnosis, staging, restaging, and surveillance of hematologic malignancies (lymphoma and multiple myeloma) for BCBSKS members.
Oncologic Applications Hematologic was separated from the broader PET Scanning: Oncologic Applications medical policy into a distinct policy; medical policy language was unchanged.
Updated Description and Policy sections, including removal of wording that all policy statements apply to both PET and PET/CT scans and clarifications about FDG-PET or FDG-PET/CT language.
For clinically indicated situations, PET is considered medically necessary only if results will influence treatment decisions.
Coverage Criteria for FDG-PET / PET-CT — Hematologic Malignancies
inv-01: Hodgkin and non-Hodgkin lymphoma
Covered when used for staging or restaging
inv-02: Multiple myeloma
Covered when used for staging or restaging
inv-03: Lymphoma: Supported Uses
Covered when evidence supports diagnostic, staging, restaging, or treatment-response use in lymphoma:
Surveillance PET is not routinely supported due to high false-positive rates; management decisions should not be made on PET alone.
inv-04: Multiple Myeloma: Supported Uses
Covered when evidence supports diagnostic, staging, or restaging use in multiple myeloma:
Routine surveillance PET is not supported.
inv-05: Surveillance: Not Supported
Not covered or limited uses:
Management should require clinical or pathologic correlation before changes.
inv-06: Covered oncologic indications (national FDG PET coverage)
National FDG PET coverage table: coverage stance by cancer type and by 'Initial' vs 'Subsequent' treatment strategy.
See listed cancer-specific entries
FDG-PET or FDG-PET/CT used as routine surveillance in asymptomatic patients is considered experimental/investigational and may be denied. Surveillance is defined as imaging performed ≥6 months after completion of cancer therapy (≥12 months for lymphoma) in individuals without objective signs or symptoms of recurrence; scans meeting that definition fall outside covered indications in this policy. [[Do not include this bracketed note]]
Guidelines support FDG-PET/CT for diagnostic workup, staging, restaging, and evaluation of treatment response in lymphoma, but they explicitly caution against routine surveillance and recommend clinical or pathologic correlation before management changes. For multiple myeloma, evidence reviews and NCCN guidance do not support routine PET/CT or whole-body MRI for routine assessment of treatment response; PET use should be tied to a specific diagnostic or management question. [[Do not include this bracketed note]]
National coverage determinations vary by cancer type: for example, prostate cancer is listed as Non-cover for the Initial Treatment Strategy (initial staging) but is covered for Subsequent Treatment Strategy (restaging/monitoring). Coverage determinations presume PET results will influence treatment decisions. [[Do not include this bracketed note]]
Surveillance FDG-PET or FDG-PET/CT in asymptomatic patients performed more than 6 months after therapy (or ≥12 months for lymphoma) is considered surveillance and is labeled experimental/investigational or not medically necessary under this policy; such timing thus places scans at risk for noncoverage absent objective signs or symptoms. [[Do not include this bracketed note]]
When PET results will not influence treatment decisions, the procedure is considered not medically necessary. The policy assumes that PET is medically necessary only if findings will alter management; otherwise the scan is excluded from coverage. [[Do not include this bracketed note]]
The policy explicitly states that FDG-PET or FDG-PET/CT is not medically necessary if the results will not influence treatment decisions. Documentation should therefore demonstrate the expected impact of the scan on staging or management to justify medical necessity. [[Do not include this bracketed note]]
Procedure Codes and Radiotracer References
| 18F-FDG | Fluorine-18 fluorodeoxyglucose radiotracer referenced for PET imaging |
| No codes listed |
| 78608 | Brain imaging, positron emission tomography (PET); metabolic evaluation |
| 78609 | Brain imaging, positron emission tomography (PET); perfusion evaluation |
| 78811 | Positron emission tomography (PET) imaging; limited area (e.g. Chest, head/neck) |
| 78812 | Positron emission tomography (PET) imaging; skull base to mid-thigh |
| 78813 | Positron emission tomography (PET) imaging; whole body |
| 78814 | Tumor imaging, PET with concurrently acquired CT; limited area (e.g. chest, head/neck) |
| 78815 | Tumor imaging, PET with concurrently acquired CT; skull base to mid-thigh |
| 78816 | Tumor imaging, PET with concurrently acquired CT; whole body |
| A9552 | Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose, up to 45 millicuries |
| A9597 | PET radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified |
Provider Requirements, Prior Authorization, and Documentation
Prior Authorization for PET/CT
Prior authorization is required for PET/CT studies in oncologic indications. Requests must specify the clinical indication and provide documentation that the scan is expected to influence patient management (e.g., staging, restaging for suspected recurrence, or initial workup when PET/CT is the chosen modality).
- A clear statement of purpose (staging, restaging for suspected recurrence, detection of progression, initial workup for solitary extraosseous plasmacytoma, etc.)
- Relevant prior imaging/results (CT, MRI, skeletal survey) and why PET/CT adds value
- Timing relative to therapy completion (surveillance scans >6 months or >12 months for lymphoma are generally not supported)
Prior authorization: indicate purpose and expected management impact
When submitting a prior authorization, indicate the specific purpose of the PET/CT and describe how the result is expected to change management (for example: guide systemic therapy selection, determine need for biopsy or radiation, alter number of chemotherapy cycles, or detect progression when other testing is inconclusive). Vague indications such as "surveillance" without clinical concern are insufficient.
- State whether the scan is for initial staging, restaging for suspected recurrence, response assessment informing therapy change, or detection of progression.
- If used to guide therapy, document the management decision pathways that will depend on positive vs negative PET findings.
Surveillance Denial Risk
Surveillance PET/CT carries a high denial risk. PET/CT performed in asymptomatic patients more than 6 months after completion of therapy (≥12 months for lymphoma) without objective signs or symptoms of recurrence is considered experimental/investigational and is routinely not covered.
- Surveillance imaging defined as asymptomatic patients >=6 months post-therapy (>=12 months for lymphoma).
- NCCN guidance: routine surveillance PET is not recommended due to false positives and should not be done routinely.
Routine response assessment in multiple myeloma not endorsed
Routine response assessment in multiple myeloma with PET/CT is not endorsed for all patients. PET/CT may be used selectively for staging/restaging, particularly when skeletal survey is negative or when PET/CT was used at baseline and will be used to monitor progression, but it is not a routine treatment-response test for every patient.
- NCCN does not recommend routine FDG-PET/CT or whole-body MRI for treatment response assessment in multiple myeloma.
- Use PET/CT selectively when it will influence management (e.g., detect progression or when baseline PET/CT exists).
Denial risk when scan won't change management
If the PET/CT results are unlikely to change treatment decisions, the scan may be considered not medically necessary and denied. Prior authorization reviewers will assess whether the proposed imaging will influence management.
- Provide documentation of the specific clinical question and the management options contingent on scan findings.
- Examples of scans at high risk for denial: routine surveillance in asymptomatic members, duplicate imaging without new indications, or scans performed when treatment plans are already finalized and not contingent on imaging.
Benefit and Indication Verification
Verify member benefits and medical necessity prior to scheduling PET/CT. Ensure that the indication aligns with the policy's covered uses (diagnosis, staging, restaging for suspected recurrence) and that surveillance exclusions are considered.
- Confirm member eligibility and any plan-specific imaging coverage rules with BCBSKS Customer Service.
- Document prior non-diagnostic or inconclusive imaging (CT, MRI, skeletal survey) when PET/CT is being requested as the next diagnostic step.
Documentation to justify medical necessity
Provide complete documentation to justify medical necessity: clinical history, signs or symptoms prompting the study, prior imaging reports, dates of treatment completion, and how PET findings will affect management. For lymphoma, include Deauville scoring when applicable and correlate PET findings with clinical and pathologic data.
- Clinical problem list and objective findings (e.g., new/worsening symptoms, abnormal labs, or focal findings on other imaging).
- Dates and types of recent cancer-directed therapies and timing relative to requested scan.
- For lymphoma, include Deauville 5-point score or request that it be reported, and note that management decisions should not rely on PET alone without clinical/pathologic correlation.
Imaging sequence consideration
Imaging sequence considerations: PET/CT is typically used after standard imaging (CT, MRI, skeletal survey) is inconclusive or when CT/MRI are contraindicated. For multiple myeloma, consider PET/CT particularly if skeletal survey is negative or when PET/CT was obtained at baseline and will be used for follow-up.
- Document prior standard imaging and reasons PET/CT is needed (inconclusive results, contraindication to contrast, or specific clinical question).
- When PET/CT detects ≥3 skeletal lesions in lymphoma workup, marrow biopsy may be unnecessary per NCCN guidance.
Imaging Sequence for Multiple Myeloma
Imaging sequence for multiple myeloma: use PET/CT as an option for initial workup and for restaging when it will inform management. PET/CT is first choice for solitary extraosseous plasmacytoma and may be used to detect progression; however, it is not mandated as routine for response assessment.
- Prefer PET/CT when skeletal survey is negative or inadequate to detect focal lesions.
- If PET/CT is used at baseline, document intent to use the same modality for subsequent assessments that will guide management decisions.
Document PET-based therapy adjustment
When PET results lead to therapy changes, document the PET-based therapy adjustment in the medical record and in the prior authorization request (e.g., escalation, de-escalation, change in radiation field, need for biopsy). Records should clearly link PET findings to the intended management change.
- State the anticipated treatment decisions contingent on positive vs negative PET findings.
- Include references to trial- or guideline-based algorithms (for example, PET-directed cycle adjustments in Hodgkin lymphoma) when applicable.
Background and Evidence Summary
Positron emission tomography (PET) with positron-emitting tracers—most commonly F-18 FDG—images metabolic activity and can detect disease not seen on conventional imaging. PET may be useful for initial staging or restaging of hematologic malignancies (Hodgkin and non-Hodgkin lymphoma, multiple myeloma) when results are expected to influence management. However, routine surveillance in asymptomatic individuals is not supported by the evidence or guideline recommendations and is associated with high false-positive rates; therefore surveillance scans beyond the policy-defined timing windows (≥6 months after therapy; ≥12 months for lymphoma) are considered experimental/investigational or not medically necessary. Providers should verify member benefits and document the indication and expected management impact when ordering FDG-PET or FDG-PET/CT. [[Do not include this bracketed note]]
Definitions and Scoring Systems
Line of Therapy Applicability
inv-37: initial and restaging
inv-38: first-line
Documentation of PET result is required to justify therapy changes.
inv-39: initial_and_subsequent
Refer to national coverage table entries for specifics
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.